Key Drivers
- Quarterly turnaround
- Negative equity
- Low cash
AIAI Summary
OMER's investment case has shifted to proving that YARTEMLEA can sustain $28M+ quarterly revenue and positive cash flow, which could accelerate deleveraging, but its single-product concentration and $297M debt load make any adoption or reimbursement shortfall highly consequential.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Quarterly turnaround
- •Negative equity
- •Low cash
OMER's strong quarterly profitability and cash generation improve its outlook, but negative equity, low cash, and historical losses keep balance-sheet risk elevated.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Sellers Active
- •Breakout Needed
OMER remains volatile and cautiously positioned last month, with $17.15–$17.35 support holding but a break below it bearish, while a sustained move above $19.25–$19.40 would improve the outlook.
Sharp early-August surge to a $19.40 peak followed by a volatile pullback
Sentiment & News
Key News Insights:
- •BlackRock Stake
- •Golden Cross
- •Momentum Focus
BlackRock's 8.35% stake and bullish technical signals strengthen institutional and momentum interest in Omeros.
Increased institutional ownership may support positive sentiment for OMER, though operational fundamentals remain undisclosed
Similar Companies in Healthcare
Other companies in the same sector with AI ratings